Regulatory Update

Olathe, Kansas – October 14, 2026 -- Avcon Industries, a subsidiary of Butler National Corporation (OTCQX: BUKS), has received FAA Supplemental Type Certificate No. ST12439CH to replace Honeywell Aerospace Mark V EGPWS computers with the MKV-A unit across nine Learjet and Bombardier models.

STC covers Learjet 40/45 and 60 and seven Bombardier variants

The Approved Models List STC applies to the Learjet Models 40/45 and 60. It also covers the Bombardier CL-600-1A11 (600), CL-600-2A12 (601), three CL-600-2B16 variants (601-3A, 601-3R and 604), BD-700-1A10 and BD-700-1A11.

The installation uses existing avionics racks and is designed to minimize installation effort. Honeywell is phasing out the Mark V, and the MKV-A is offered as a drop-in replacement with options to upgrade capabilities later.

Washington – October 14, 2026 -- Two state-specific versions of Teaching Strategies' flagship curriculum, The Creative Curriculum for Preschool and The Creative Curriculum for Pre-K, have received a "Tier 1" designation, the highest rating available from the Louisiana Department of Education.

Both versions are approved and available for use in Louisiana early childhood classrooms. The designation recognizes strong alignment with Louisiana's Birth to Five Early Learning and Development Standards. Teaching Strategies says The Creative Curriculum is the only curriculum designed to work with its GOLD assessment.

Oyo State, Nigeria – October 13, 2026 -- KuCoin Nigeria Limited has received conditional Approval-in-Principle (AIP) from the Securities and Exchange Commission, Nigeria (SEC Nigeria) for admission into its Accelerated Regulatory Incubation Programme (ARIP), but the approval does not allow it to operate in the country.

AIP is not a licence and does not permit client onboarding

SEC Nigeria's conditional AIP is not a final registration, licence, endorsement or recommendation. It does not authorise KuCoin Nigeria to commence operations, onboard clients or offer services to the Nigerian public. The company states that admission into ARIP does not assure or predetermine the grant of formal registration.

Amsterdam – October 13, 2026 -- YeePay has been granted an Electronic Money Institution (EMI) license by De Nederlandsche Bank (DNB), the Dutch central bank, giving the cross-border payments provider a second European EMI authorization after its existing UK license.

Dutch license adds to a multi-jurisdiction regulatory portfolio

The Netherlands is a major financial hub within the European Union. YeePay said the approval strengthens its regulatory footprint and supports compliant, localized payment services for businesses operating across international markets, subject to applicable regulatory requirements.

The company's existing licenses and registrations include:

Shanghai – October 13, 2026 -- Shanghai Ark Biopharmaceutical (ArkBio) has received U.S. Food and Drug Administration clearance of its investigational new drug application for AK0406, allowing a phase II trial of the long-acting antiviral drug-Fc conjugate for influenza prevention in the general U.S. population.

CDC data shows 24,000 U.S. flu deaths despite vaccines

The U.S. Centers for Disease Control and Prevention reports that the 2025–2026 influenza season caused at least 32 million illnesses, 380,000 hospitalizations and 24,000 deaths in the United States. ArkBio says shifting circulating viruses and variable immune response limit vaccine protection, particularly among older adults and immunocompromised people.

Menlo Park – October 13, 2026 -- Endovascular Engineering, Inc. (E2) has received U.S. FDA 510(k) clearance for both the Hēlo Thrombectomy System and Hēlo Return, a blood return system the company describes as the first cleared for use with continuous vacuum aspiration.

FDA clears two devices for pulmonary embolism treatment

The Hēlo platform is built for treating pulmonary embolism (PE). The FDA's decision followed its review of clinical data from the ENGULF IDE study, which demonstrated safety and efficacy of the Hēlo Thrombectomy System. E2 says it is now accelerating plans to bring the platform to a broad range of physicians and patients.

Beijing – October 13, 2026 -- T-MAXIMUM PHARMACEUTICAL has received FDA clearance to start a Phase 2 study of MT027, its B7-H3-targeted allogeneic CAR-T therapy, in patients with brain metastases from lung and breast cancer. It is the second Phase 2 program for the asset to clear the agency.

MT027 now has two FDA-cleared Phase 2 programs in intracranial solid tumors

The FDA previously cleared a Phase 2 study of MT027 in recurrent glioblastoma. The therapy holds Orphan Drug Designation and Fast Track Designation. The two programs give T-MAXIMUM a dual-indication portfolio covering both primary and metastatic intracranial solid tumors.

Taipei – October 12, 2026 -- China's National Medical Products Administration (NMPA) has approved CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for adult patients with advanced prostate cancer, Foresee Pharmaceuticals (TPEx: 6576) said. Licensing partner Changchun GeneScience Pharmaceutical (GenSci) notified Foresee of the approval of the Marketing Authorization Application and will commercialize the product in China.

GenSci holds exclusive China rights across all CAMCEVI indications

The license covers all current and pipeline indications: advanced prostate cancer, central precocious puberty (CPP) and premenopausal breast cancer. Foresee Chairman and CEO Ben Chien said GenSci's China launch will "significantly contribute" to the growth of the company's global CAMCEVI franchise.

Toronto – October 12, 2026 -- 3iQ Middle East Ltd, the UAE-based sister company of digital asset manager 3iQ Corp., has secured In-Principal Approval (IPA) for a Category 4 license from the Financial Services Regulatory Authority (FSRA) of Abu Dhabi Global Market (ADGM).

The IPA is an interim step, and 3iQ must still complete the licensing process. ADGM's Chief Market Development Officer, Arvind Ramamurthy, said the regulator looks forward to supporting 3iQ as it progresses through that process.

3iQ ties the approval to a plan for licensed presence in all major digital asset hubs

The company said the IPA is part of its aim to be regulated and present in all major digital asset hubs globally. That would make its investment offering accessible to accredited investors worldwide, including the first Bitcoin and Ethereum ETFs listed on a major stock exchange.

Kuala Lumpur – October 12, 2026 -- ASEAN Records Sdn. Bhd. has secured Indonesian trademark registration No. IDM001511852 for its logo and "Celebrates Regional Excellence" tagline, with protection running to 27 March 2036 under Class 41.

Indonesian IP authority recorded registration under Law No. 20 of 2016

Indonesia's Directorate General of Intellectual Property, part of the Ministry of Law, recorded the registration on 21 September 2026 under Application No. JID2026027569. The filing date was 27 March 2026. The protection period runs from 27 March 2026 to 27 March 2036 and is subject to renewal. The registration was made under Indonesia's Law No. 20 of 2016 concerning Marks and Geographical Indications.

Class 41 filing covers award ceremonies, conferences and cultural events

The registration covers the following services: